Person: ÇELİK, BURAK
3 results
Search Results
Now showing 1 - 3 of 3
Publication Metadata only Evaluation of Wound Healing Potential of New Composite Liposomal Films Containing Coenzyme Q10 and D-Panthenyl Triacetate as Combinational Treatment.(2021-02-13T00:00:00Z) Sağıroğlu, Ali Asram; Çelik, Burak; Güler, Eray Metin; Koçyiğit, ABDÜRRAHİM; Özer, Özgen; ASRAM SAĞIROĞLU, ALİ; ÇELİK, BURAK; KOÇYİĞİT, ABDÜRRAHİMPublication Open Access Targeted Nanomedicines for Cancer Therapy, From Basics to Clinical Trials(2020-04-30T00:00:00Z) Eskandari, Zahra; BAHADORİ, FATEMEH; ÇELİK, BURAK; Onyuksel, Hayat; BAHADORİ, FATEMEH; ÇELİK, BURAKTraditional systemic chemotherapy involves the wide distribution of drug molecules in the body, causing toxic side effects in the healthy tissues and limiting the therapeutic dose required at the site of drug action. In order to decrease side effects and increase the drug efficacy, recent research on chemotherapy focuses on drug targeting. Targeted therapy can be achieved by several mechanisms including; 1) using an antibody as a drug that is specific to a disease biomarker, 2) using an antibody (or peptide) as a targeting agent conjugated to the drug molecule, 3) delivering the drug molecules to the target tissue in a nano-carrier with or without the targeting agent attached on its surface. The third approach involves the nanomedicines that can be targeted to diseased tissues by both passive (extravasating at diseased sites due to leaky vasculature) and active (specific interaction of the targeting agent with disease biomarker) targeting mechanisms. In this review we will cover the passively targeted nanomedicines prepared using nano drug carriers. Ideally the carrier particle should be in the right size (1-100nm), stable enough to prevent drug leakage during circulation, and safe not to cause any damage to healthy tissues. Competition for all these properties generated many different types of materials to be used as nanodrug delivery systems. After a brief review of most commonly used drug carriers, we discuss the clinical use of the targeted nanomedicines with regard to their pharmacokinetic and pharmacodynamics properties, and how these properties vary from conventional formulations providing free drugs in the circulation after administration.Publication Metadata only INFLUENCE OF VEHICLES AND PENETRATION ENHANCERS ON ANTI-INFLAMMATORY EFFECT OF 18-beta GLYCYRRHETINIC ACID: KINETIC MODELLING OF DRUG RELEASE, IN VIVO AND EX VIVO EXPERIMENTS(2020-07-01T00:00:00Z) Karaman, Ecem Fatma; ÇELİK, BURAK; Ozdemir, Samet; Tekkeli, Evrim Kepekci; Demirkoz, Asli Barla; Gonullu, Umit; Uner, Melike; ÇELİK, BURAK; TEKKELİ, ŞERİFE EVRİMTopical formulations of 18-beta glycyrrhetinic acid (18-beta GA) were designed for use in relieving inflammatory and painful conditions of the skin. Formulations were containing penetration enhancers that differ in penetration enhancing mechanisms. Anti-inflammatory effects of formulations and effects of penetration enhancers on penetration and permeation of the drug through rat skin were investigated. The total amount of 18-beta GA permeated from the base oil/water emulsion (53.19 +/- 22.25 mcg/cm(2) ) was approximately twice higher than the base oleaginous cream (29.17 +/- 3.85 mcg/cm(2)) while there was no 18-beta GA permeation from the base hydrogel formulation to the skin (p < 0.05). Incorporation of propylene glycol was generally found to increase 18-beta GA permeation to the skin. The highest oedema inhibiting activity was achieved in the oil/water emulsion containing propylene glycol followed by the base oil/water emulsion without a penetration enhancer (p < 0.05). This result was consistent with the ex vivo study. Limonene and oleic acid were found to be insufficient in 18-beta GA permeation to the skin.